What Happens When A Silent Disease Becomes Knowable

Alzheimer’s doesn’t wait for a diagnosis to begin. The brain changes can start quietly for years, even a decade, while someone looks totally fine, passes cognitive tests, drives, works, and pays the same routine healthcare bills as their peers. That raises a tough question with massive public health stakes: if the disease is already active, when does it start costing Medicare real money?

We dig into a 2026 Journal of Prevention of Alzheimer’s Disease study that finally connects two missing halves of the puzzle: precise clinical trial data from cognitively normal adults with confirmed amyloid pathology, and real-world Medicare claims that record hospital stays, ER visits, home health care, and actual dollars spent. The surprising baseline finding is a true economic paradox: elevated amyloid alone does not meaningfully raise healthcare utilization or Medicare payments. The spending surge arrives later, when cognitive decline becomes disruptive enough to show up in claims and when frailty ramps up.

The most important takeaway is what drives the spike. It is not primarily dementia-specific treatment. Costs jump because slipping executive function makes everyday chronic disease management fall apart, turning “cheap” conditions like hypertension or diabetes into emergencies like falls, injuries, surgeries, and long recovery stays. We also talk about the detection gap between sensitive research tools and rushed primary care, why cognitive reserve may delay the tipping point for highly educated cohorts, and the provocative next frontier: if blood tests like p-tau217 make preclinical Alzheimer’s visible to everyone, does knowledge alone change behavior and spending before symptoms begin?

If this changed how you think about Alzheimer’s prevention, share it with someone who needs it, and subscribe, rate, and review so more people can find the show.

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Transcript

Hidden Timeline Of Alzheimer’s Costs

SPEAKER_01 0:00

Usually um when we think about the financial impact of a serious disease, we just assume there's a clear starting gun, right?

SPEAKER_00 0:06

Right. A a formal diagnosis.

SPEAKER_01 0:07

Aaron Ross Powell Exactly. A doctor sits you down, hands over the diagnosis, and immediately, bam, the medical bills start piling up.

SPEAKER_00 0:14

Aaron Powell Yeah, that's the traditional expectation.

SPEAKER_01 0:16

Aaron Powell It's just a simple linear progression. You know, you get sick, your health care costs increase. But um when you look at a neurodegenerative condition like Alzheimer's disease, that timeline completely shatters.

SPEAKER_00 0:29

Oh, it really does.

SPEAKER_01 0:30

The starting gun actually goes off years, sometimes even a full decade, before anyone even hears the starting pistol.

SPEAKER_00 0:35

Aaron Powell Right. It's totally silent.

SPEAKER_01 0:37

So, okay, let's unpack this because today for our deep dive, we're looking at a 2026 study from the Journal of Prevention of Alzheimer's Disease.

SPEAKER_00 0:45

Yeah. And it's a really pivotal one.

SPEAKER_01 0:47

Aaron Powell It's titled Uh Increase in Healthcare Utilization and Medicare Payment with Progression of Preclinical Alzheimer's Disease.

SPEAKER_00 0:54

Yeah.

SPEAKER_01 0:54

And we are on a mission today to explore this hidden timeline.

SPEAKER_00 0:58

Aaron Powell Which is so crucial for everyone to understand. This is really a first-of-its kind exploration into the economic impact of that preclinical stage.

SPEAKER_01 1:07

Aaron Powell Because usually researchers are kind of walled off, right?

SPEAKER_00 1:10

Trevor Burrus Yeah, exactly. Historically, you have two totally distinct types of information. On one hand, you've got clinical trial data.

SPEAKER_01 1:17

The highly controlled stuff.

SPEAKER_00 1:19

Right. It meticulously tracks biology and objective cognitive scores in this pristine laboratory setting. But on the other hand, you have Medicare claims data. Trevor Burrus, Jr.

SPEAKER_01 1:29

Which is, I mean, basically just a messy, sprawling spreadsheet of actual human behavior.

SPEAKER_00 1:33

Trevor Burrus, Jr.: You know, ER visits, hospital stays, the exact dollar amounts the government is spending. Right. And this study is groundbreaking because they finally managed to bridge that gap. They securely linked precise clinical trial data to real-world Medicare claims to map out exactly when this biological disease starts costing the system money.

SPEAKER_01 1:53

Aaron Powell Which is wild. So to really grasp the findings for you listening, we need to completely separate the biological definition of Alzheimer's from the clinical diagnosis of dementia.

SPEAKER_00 2:04

Aaron Powell Yes. That distinction is absolutely key.

SPEAKER_01 2:07

Aaron Powell Because if you're keeping up with neurodegenerative research, you know the diagnostic criteria have rapidly evolved. We aren't just looking at memory loss anymore.

SPEAKER_00 2:16

Not at all.

SPEAKER_01 2:16

The study focuses entirely on the Alzheimer's continuum, specifically stages one and two, right?

SPEAKER_00 2:22

Aaron Ross Powell Yeah, which represent the preclinical stage.

SPEAKER_01 2:24

Aaron Powell So what does that actually look like for a person?

SPEAKER_00 2:26

Aaron Ross Powell Well, in this preclinical phase, the individual is cognitively unimpaired. I mean, if you sat down and had a lengthy conversation with them, or even gave them a standard cognitive test, they would pass with flying colors.

SPEAKER_01 2:39

They're totally fine on the outside.

SPEAKER_00 2:41

Exactly. They're driving, they're managing their finances, living entirely independent lives. But beneath the surface, the biological machinery of the brain is actively failing.

SPEAKER_01 2:51

That's the scary part.

SPEAKER_00 2:52

We are looking at the steady accumulation of amyloid beta proteins. They clump together to form these sticky plaques between the neurons, and it essentially disrupts cell-to-cell communication.

SPEAKER_01 3:03

Aaron Powell And it isn't just the amyloid plaques outside the cells, right? Inside the neurons, the tau proteins are basically collapsing.

SPEAKER_00 3:09

Aaron Powell Yeah, that is the secondary hallmark. So tau proteins normally act like think of them like railroad

What Preclinical Alzheimer’s Really Means

SPEAKER_00 3:15

ties.

SPEAKER_01 3:15

Aaron Powell Okay, railroad ties.

SPEAKER_00 3:16

Aaron Ross Powell Right. They keep the internal transport tracks of brain cells perfectly straight, so nutrients can flow from one end of the cell to the other. Oh wow. But during this preclinical stage, those tau proteins become hyperphosphorylated. They detach from the tracts, the tracts completely collapse, and the tau proteins themselves tangle up into these chaotic knots.

SPEAKER_01 3:35

So they're effectively starving the cell from the inside out.

SPEAKER_00 3:38

Exactly. That's exactly what's happening.

SPEAKER_01 3:40

And we also see the evidence of this internal collapse leaking out of the brain entirely, don't we? The study highlights elevated biomarkers, um, like peta 217 in the blood.

SPEAKER_00 3:51

Right, because as those tau tangles form and the neurons degrade, fragments of these proteins are cleared out of the brain into the cerebrospinal fluid.

SPEAKER_01 4:01

And then they eventually cross the blood-brain barrier.

SPEAKER_00 4:03

Yep, they enter the bloodstream. And that is how a simple armprick at a lab can reveal this profound structural damage happening deep inside the brain.

SPEAKER_01 4:12

It's incredible that we can see that now. But I mean, if we connect this to the bigger picture, the sheer scale of this invisible stage is staggering.

SPEAKER_00 4:21

Oh, the numbers are huge.

SPEAKER_01 4:23

Based on current data, an estimated 6.7 million Americans aged 55 to 64.

SPEAKER_00 4:29

And an astonishing 9.9 million aged 65 to 79.

SPEAKER_01 4:33

Right. Almost 10 million people in that older bracket currently harbor this amyloid buildup and the underlying pathology without any objective cognitive decline.

SPEAKER_00 4:43

It's really wild to think about. That is millions of people walking around with the active biology of Alzheimer's totally unaware because their cognitive function hasn't dropped below that clinical threshold yet.

SPEAKER_01 4:53

Aaron Powell The best way I can describe this for you is well, it's like having termites in your house.

SPEAKER_00 4:58

Oh, that's a perfect analogy.

SPEAKER_01 4:59

Right. The biological foundation is actively being eaten away day by day, month by month. But you know, the walls haven't started to sag yet, the roof isn't leaking.

SPEAKER_00 5:08

You'd walk through the living room and think the house looks absolutely perfect.

SPEAKER_01 5:11

Aaron Powell Exactly. You wouldn't know the termites were there without a highly specialized inspection, like um an amyloid PT scan or one of those advanced biomarker blood tests. Right. So the core question this study tackles is how do you track the financial footprint of a completely invisible disease? How do we see when those termites actually start affecting the house's value?

SPEAKER_00 5:32

And the researchers solved this by tracking two incredibly rigorous observational trials. The primary group is the A4 Medicare cohort.

SPEAKER_01 5:40

Which stands for anti-amyloid treatment in asymptomatic Alzheimer's.

SPEAKER_00 5:43

Exactly. They isolated 246 participants aged 65 to 85. Every single one of these individuals was cognitively normal, but they had elevated brain amyloid definitively confirmed by PEAT scans.

SPEAKER_01 5:56

Okay, so they definitely had the foundational damage. They had the termites.

SPEAKER_00 5:59

Precisely. And then to create a baseline comparison, they utilized the Learn Medicare cohort.

SPEAKER_01 6:04

LEARN

Bridging Trial Data With Medicare

SPEAKER_01 6:05

being longitudinal evaluation of amyloid risk and nerdy generation.

SPEAKER_00 6:08

You got it. This served as the control group. It consisted of 121 participants who were also completely cognitively normal, but crucially, their PE scans showed no elevated amyloid.

SPEAKER_01 6:23

So their brains were completely clear of that primary pathology.

SPEAKER_00 6:26

Right, no termites.

SPEAKER_01 6:28

Okay, but looking at this methodology, my mind immediately jumps to a functional question. I mean, the administrative and privacy hurdles to connect tightly controlled anonymized clinical trial data to someone's actual government Medicare billing history, that must be astronomical.

SPEAKER_00 6:45

Oh, it's a massive, massive headache for researchers.

SPEAKER_01 6:47

Aaron Powell So why go through all that trouble? If you already have these two groups under a microscope in a clinical trial, why not just look at the trial's internal data? Yeah. You could see how they progress and estimate the cost from there, couldn't you?

SPEAKER_00 6:57

Aaron Powell Well, you'd think so, but clinical trials happen in a sterile vacuum. They are phenomenal at tracking objective biology. They can tell you if a patient's brain volume shrank by a millimeter or if they scored, you know, one point lower on a specialized memory test.

SPEAKER_01 7:11

But they miss the real world.

SPEAKER_00 7:12

Exactly. A clinical trial cannot tell you what happens when that same patient goes home. Medicare claims data tracks the chaotic reality of everyday human life.

SPEAKER_01 7:22

Aaron Powell Which is where the actual money is spent.

SPEAKER_00 7:24

Right. A Medicare claim reveals if that microscopic brain shrinkage caused the patient to misjudge a step, fall down their front stairs, end up in a trauma center, and eventually need a two-week stay in a skilled nursing facility.

SPEAKER_01 7:37

Wow, yeah. It bridges the gap between laboratory science and everyday life.

SPEAKER_00 7:42

It tells you exactly how many taxpayer and out-of-pocket dollars were spent to treat the real-world consequences of that biological decline.

SPEAKER_01 7:49

So, okay, we have our two groups, the A4 group with a hitting disease and the learned group without it. What did their lives and their healthcare bills look like during the baseline period before any clinical cognitive decline actually kicked in?

SPEAKER_00 8:02

The baseline findings are fascinating because they challenge a fundamental assumption about disease economics.

SPEAKER_01 8:07

Oh, so.

SPEAKER_00 8:08

Before the study officially tracked progression, the A4 participants and the learned participants had almost identical overall healthcare utilization and Medicare payments.

SPEAKER_01 8:17

Wait, wait, let me make sure I'm grasping the scale of this. Having active progressing Alzheimer's pathology in your brain doesn't cost the system a single extra dollar in the beginning.

SPEAKER_00 8:28

The statistical analysis showed no significant difference at all.

SPEAKER_01 8:32

That is wild.

SPEAKER_00 8:33

The A4 group's average total Medicare payment was $449 per person per month. The LEARN group averaged $394 per month.

SPEAKER_01 8:42

Basically the same. So what were they even going to the doctor for?

SPEAKER_00 8:45

Both groups were just visiting primary care doctors for standard age-related maintenance. Around 72 to 73% of participants in both cohorts were managing lipid disorders, like high cholesterol.

SPEAKER_01 8:58

Right, totally normal aging stuff.

SPEAKER_00 9:00

Yeah, and roughly half were being treated for hypertension.

SPEAKER_01 9:03

Here's where it gets really interesting because this highlights a massive economic paradox. You have the physical biology of a terminal, highly destructive neurodegenerative disease operating in your brain, yet your medical footprint looks exactly like someone whose brain is completely healthy.

SPEAKER_00 9:18

Yes. What's fascinating here is how the researchers validated this lack of physical burden using the JN frailty index or the JFI.

SPEAKER_01 9:26

Oh, right, the claims-based measure.

SPEAKER_00 9:29

Exactly. It's a brilliant tool that calculates physical frailty entirely based on insurance claims. Instead of a doctor physically examining a patient's gate, the JFI looks for specific billing codes.

SPEAKER_01 9:42

Like orders for walkers or home health visits.

Baseline Costs Stay Surprisingly Flat

SPEAKER_00 9:45

Precisely. And at baseline, the JFI scores were functionally identical between the A4 and LERN cohorts. The vast majority were categorized as having low frailty.

SPEAKER_01 9:55

So the pathology is actively destroying the internal structure of the neurons, but the person is still walking, talking, and managing their cholesterol just fine.

SPEAKER_00 10:03

Yep. The system is bearing zero extra weight during this preclinical window.

SPEAKER_01 10:08

It proves there's this window of opportunity where the biological presence of the disease is there, but the economic and clinical avalanche just hasn't started falling down the mountain yet.

SPEAKER_00 10:18

But you know, the biological bill always comes due.

SPEAKER_01 10:20

Right, the dipping point.

SPEAKER_00 10:21

Exactly. When the underlying pathology finally causes enough structural damage to overwhelm the brain's compensatory mechanisms, we enter the on-study period. Over time, the A4 group, the ones with the amyloid, naturally experienced faster cognitive decline.

SPEAKER_01 10:38

And when that progression was officially logged into their Medicare claims, the costs didn't just inch upward, they completely exploded.

SPEAKER_00 10:45

Oh, it was a dramatic shift.

SPEAKER_01 10:47

Let's look at the specific financial triggers here. Because when an individual in the A4 group received a Medicare billing code for cognitive impairment, it triggered a 45% increase in total Medicare spending compared to the non-progressors.

SPEAKER_00 11:01

Which translates to an extra $140 per month.

SPEAKER_01 11:05

And if the decline progressed to a formal Alzheimer's disease diagnosis code, the burden jumped by 66%. That's an extra $207 per month.

SPEAKER_00 11:13

And the physical frailty metric, that JFI score we talked about, is where the numbers become truly catastrophic.

SPEAKER_01 11:19

Yeah, tell them about the JFI numbers.

SPEAKER_00 11:20

If a progressing patient's JN frailty index score hit a six or higher meaning high frailty, it caused a 103% increase in healthcare payments.

SPEAKER_01 11:29

Over double.

SPEAKER_00 11:29

Right. An extra $303 per month, working out to over $3,600 a year in additional Medicare spending for a single person.

SPEAKER_01 11:38

Aaron Powell But wait, I want to push back on this a little bit or at least clarify something. Because when someone hears about a 66% cost increase right after an Alzheimer's diagnosis, the knee-jerk assumption is that the money is going toward the disease itself.

SPEAKER_00 11:52

Oh, sure. You'd assume it's for new dementia medications.

SPEAKER_01 11:54

Aaron Powell Exactly. Or billing the system for weekly visits to a highly specialized neurologist are these extra costs just from that?

SPEAKER_00 12:02

Aaron Ross Powell That is the most common misconception. But the Medicare claims data thoroughly debunks it. Really? Yeah. The massive spending spikes are not driven by dementia-specific treatments. They are actually driven by systemic ripple effects. The data reveals sudden, sharp increases in inpatient hospital stays, outpatient emergency room visits, and extensive home health utilization.

SPEAKER_01 12:23

Ah, okay. So it's the collapse of executive function causing a cascade of other medical crises.

SPEAKER_00 12:29

Precisely. Think about the baseline data. You have a patient who has successfully managed their diabetes and hypertension for decades.

SPEAKER_01 12:36

Right. They know exactly when to take their insulin.

SPEAKER_00 12:38

But as preclinical Alzheimer's progresses, the executive function required to execute that complex daily routine begins to slip. The management of those existing comorbidities just

The Tipping Point When Costs Explode

SPEAKER_00 12:50

falls apart.

SPEAKER_01 12:50

So they forget a meal or take their blood pressure medication twice.

SPEAKER_00 12:54

Aaron Ross Powell Exactly. And that rapidly leads to syncope or fainting. They lose consciousness in the kitchen, they fall, they break a hip. Wow. Suddenly, a patient who was costing the system $400 a month is in the back of an ambulance requiring emergency surgery and months of skilled nursing.

SPEAKER_01 13:12

So the brain disease itself isn't what runs up the massive hospital bill. It just makes it impossible for the patient to safely pilot the rest of their body.

SPEAKER_00 13:20

That's a great way to put it. The pathology compromises their ability to navigate their own health, turning cheap chronic conditions into incredibly expensive medical emergencies.

SPEAKER_01 13:30

Which is terrifying. But we also see this strange disconnect in the study between what a doctor sees in a trial and what shows up on a Medicare claim, don't we?

SPEAKER_00 13:39

Yes. And frankly, it's a very concerning discrepancy.

SPEAKER_01 13:42

Because in the clinical trial, researchers used a measurement called the Clinical Dementia Rating Scale Global Score, the CDRGS.

SPEAKER_00 13:50

Right, which is a highly sensitive diagnostic tool designed to catch the absolute earliest, most subtle whispers of cognitive decline.

SPEAKER_01 13:58

But here is the critical finding.5. Very mild impairment.

SPEAKER_00 14:34

Right. But real-world healthcare costs don't increase until the impairment is severe enough to cause a tangible disruption in the patient's daily life.

SPEAKER_01 14:41

It's honestly just like a car's check engine light.

SPEAKER_00 14:43

Oh, I like that. How so?

SPEAKER_01 14:45

Well, the clinical trial tests, the CDRGS, is like taking your car to a master mechanic who plugs a highly advanced computer into the dashboard. That computer finds a microscopic fault in a tiny sensor.

SPEAKER_00 14:56

But the car is still driving perfectly fine.

SPEAKER_01 14:58

Exactly. You wouldn't even notice a drop in fuel efficiency. But the mechanic's computer knows the part is failing. That is the clinical trial catching the earliest biological decline. But the Medicare claim, that's when the engine actually overheats, the car is smoking on the highway, and you have to call a tow truck.

SPEAKER_00 15:16

That is spot on. A primary care doctor in the real world simply does not have the resources to act like that master mechanic. A routine physical is what, 15 minutes?

SPEAKER_01 15:25

Yeah, if you're lucky.

SPEAKER_00 15:26

The physician is checking blood pressure, renewing a statin prescription. In that 15-minute window, a subtle cognitive decline, a 0.5 on the CDRGS is completely invisible to them. So they have no reason to input a new diagnostic billing code.

SPEAKER_01 15:41

Aaron Powell, which means there is this hidden gap. A period where the decline is technically measurable in a lab, but it hasn't yet caused enough functional damage to break your life in the real world.

SPEAKER_00 15:51

And that gap is the ultimate focus of preventative medicine. It's the final window for intervention before the financial avalanche is triggered.

SPEAKER_01 16:00

Aaron Powell So bringing all this data together, what are the implications for the listener? I mean, obviously the study concludes that delaying the progression of Alzheimer's in this preclinical stage could save massive amounts of money for Medicare. Trevor Burrus, Jr.

SPEAKER_00 16:13

Huge amounts. But looking at the study's design, there is a massive demographic caveat here.

SPEAKER_01 16:19

Aaron Ross Powell Right, we have to mention this.

SPEAKER_00 16:20

Trevor Burrus The researchers were very transparent about it. The participants in both the A4 and learn groups were predominantly white, highly proactive about volunteering for trials, and incredibly well educated.

SPEAKER_01 16:32

Aaron Powell The average participant had 17 years of education. That is essentially a master's degree.

SPEAKER_00 16:37

Aaron Powell Exactly. And in neurobiology, 17 years of rigorous education provides a massive amount of what we call cognitive

Detection Gaps And Who Gets Missed

SPEAKER_00 16:45

reserve.

SPEAKER_01 16:45

Aaron Powell Which is the brain's ability to improvise, right, to find alternate ways of getting a job done.

SPEAKER_00 16:50

Yes. A highly educated brain builds complex, redundant neural networks over a lifetime. So when the Alzheimer's pathology begins destroying specific pathways, a brain with high cognitive reserve can essentially build detours around the microscopic damage.

SPEAKER_01 17:06

They can continue to function normally and manage their medications much longer than someone with less cognitive reserve.

SPEAKER_00 17:12

Exactly. They delay the tipping point. The structural damage is happening, but their brain's internal redundancy prevents them from crashing into the healthcare system as quickly.

SPEAKER_01 17:22

Plus, that specific demographic probably has better access to private resources to manage early slip-ups, right?

SPEAKER_00 17:29

Oh, absolutely. Which implies a really harsh reality for the broader, less resourced general population. For individuals without 17 years of education, the threshold for clinical progression might be crossed much faster.

SPEAKER_01 17:42

The detours fail sooner.

SPEAKER_00 17:44

Right. So the catastrophic cost spikes we discussed could be even more severe in the general population, and they'd likely happen much earlier in the disease timeline.

SPEAKER_01 17:52

So what does this all mean for you? It means the fight against Alzheimer's isn't just about managing dementia anymore.

SPEAKER_00 17:59

It can't be. The public health policy focus has been on managing the fallout building memory care facilities, hiring home health aides.

SPEAKER_01 18:07

But this data proves the war is won by intercepting the disease while it's still completely invisible.

SPEAKER_00 18:14

The ultimate goal is applying effective disease modifying therapies during the preclinical stage. If we can halt that amyloid buildup while the patient is still cognitively normal, we aren't just saving memories.

SPEAKER_01 18:27

We are preventing that devastating transition from a silent biological state to a catastrophic economic burden.

SPEAKER_00 18:33

Exactly. Catching the failing sensor before the engine catches fire.

SPEAKER_01 18:36

To quickly summarize our deep dive today, Alzheimer's begins in the brain long before it begins in our daily lives. And the true financial devastation only erupts when clinical symptoms finally disrupt a person's ability to manage their overall health.

SPEAKER_00 18:50

Well said.

SPEAKER_01 18:51

But I want to leave you with a final, slightly provocative thought to mull over. The study proves that simply having the biology of preclinical Alzheimer's doesn't increase your healthcare costs, as long as you remain symptom-free.

SPEAKER_00 19:02

Right. Because you have no idea it's happening. The lack of awareness preserves the baseline.

SPEAKER_01 19:07

Right. But medical diagnostics are advancing so

When Early Screening Changes Spending

SPEAKER_01 19:10

fast. Highly sensitive blood tests, like for that PTOD 217 we mentioned, are moving toward commercial availability. Soon, screening for Alzheimer's might just be a standard box your doctor checks at a physical. Which is an amazing medical advancement, but what happens when the invisible forcefully becomes visible? Will simply knowing you have preclinical Alzheimer's change your healthcare utilization?

SPEAKER_00 19:33

Even with zero clinical symptoms.

SPEAKER_01 19:35

Exactly. If an armprick tells you the machinery of Alzheimer's is actively grinding away in your brain, but you feel completely fine, how does human psychology alter the spreadsheet? Will the sheer anxiety, the push for preemptive neurological care, the extra testing drive up costs immediately?

SPEAKER_00 19:51

It's a huge question. Will it fundamentally destroy the calm before the storm period?

SPEAKER_01 19:57

Will the financial burden shift years earlier just because we peered behind the curtain too soon? It is a complex

Final Takeaways And Sign Off

SPEAKER_01 20:05

economic and human dilemma that we are all going to have to grapple with very shortly. Thank you for joining us on this deep dive into the hidden timeline of Alzheimer's. Keep questioning the world around you, and we'll catch you on the next one.